2019
Effector TH17 Cells Give Rise to Long-Lived TRM Cells that Are Essential for an Immediate Response against Bacterial Infection
Vesely M, Pallis P, Bielecki P, Low JS, Zhao J, Harman CCD, Kroehling L, Jackson R, Bailis W, Licona-Limón P, Xu H, Iijima N, Pillai PS, Kaplan DH, Weaver CT, Kluger Y, Kowalczyk MS, Iwasaki A, Pereira JP, Esplugues E, Gagliani N, Flavell RA. Effector TH17 Cells Give Rise to Long-Lived TRM Cells that Are Essential for an Immediate Response against Bacterial Infection. Cell 2019, 178: 1176-1188.e15. PMID: 31442406, PMCID: PMC7057720, DOI: 10.1016/j.cell.2019.07.032.Peer-Reviewed Original ResearchConceptsCD4 TTissue-resident memory T cellsBacterial infectionsResident memory T cellsFunction of airwayLife-long protectionEffector memory TMemory T cellsTh17 cellsTRM cellsΓδ TEffector cellsMemory TBacterial clearanceT cellsIL-7Adaptive immunityMouse modelMemory responsesVaccine designHost defenseLymphatic endothelial cellsDepletion studiesEndothelial cellsCellular origin
2016
Exploiting Mucosal Immunity for Antiviral Vaccines
Iwasaki A. Exploiting Mucosal Immunity for Antiviral Vaccines. Annual Review Of Immunology 2016, 34: 575-608. PMID: 27168245, DOI: 10.1146/annurev-immunol-032414-112315.Peer-Reviewed Original ResearchConceptsMucosal immunityHuman immunodeficiency virusEffective immune protectionHost immune responseHerpes simplex virusImmunodeficiency virusMucosal vaccinesImmune protectionSuccessful vaccineImmune responseSimplex virusAntiviral vaccinesMucosal surfacesVaccine developmentVaccine designInfluenza virusFirst lineVaccineViral pathogensImmunityViral diseasesVirusDangerous pathogensPathogensDisease
2013
Generating protective immunity against genital herpes
Shin H, Iwasaki A. Generating protective immunity against genital herpes. Trends In Immunology 2013, 34: 487-494. PMID: 24012144, PMCID: PMC3819030, DOI: 10.1016/j.it.2013.08.001.Peer-Reviewed Original ResearchConceptsGenital herpesHerpes simplex virus infectionSimplex virus infectionSignificant risk factorsClinical vaccine trialsRecurrent symptomsHSV infectionProtective immunityViral sheddingVaccine trialsRisk factorsChronic diseasesVirus infectionHIV-1Clear infectionAntiviral drugsHost responseHerpesVaccine designInfectionMillions of peopleSpread of diseaseDiseaseRecent studiesVaccine